Phenotypes Associated with This Genotype

Genotype
MGI:5819053

• Allelic Composition: Apob^tm2Sgy/Apob^tm2Sgy; Apoe^tm1Unc/Apoe^tm1Unc; Lep^ob/Lep^ob
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

atherosclerotic lesions ( J:133453 )

• at 12 weeks of age, atherosclerotic lesions are seen mainly in the aortic region of the whole aorta

• leptin treatment, but not food restriction, results in lower atherosclerotic lesion size

hypertension ( J:133453 )

• elevated blood pressure

• treatment with enalapril corrects the elevated blood pressure

growth/size/body

obese ( J:133453 )

• increase in body weight, with mice weighing about 63 grams at 15-16 weeks of age

homeostasis/metabolism

hyperglycemia ( J:133453 )

• mice are hyperglycemic and glycemic control fluctuates with age

• mice show improved in blood glucose with food restriction but not with leptin treatment

increased circulating insulin level ( J:133453 )

• increase in blood insulin levels

• neither food restriction or leptin treatment has an effect on insulin level

abnormal circulating cholesterol level ( J:133453 )

• mice have higher VLDL levels than LDL, with lower HDL levels compared to wild-type mice which have HDL as the dominant lipoprotein species and very low levels of LDL and VLDL

decreased circulating HDL cholesterol level ( J:133453 )

• mice have lower HDL levels

increased circulating cholesterol level ( J:133453 )

• cholesterol levels are elevated almost 10-fold compared to wild-type mice

• both leptin treatment and food restriction result in 52.6% and nonsignificant 18.5% reduction, respectively, of cholesterol levels

increased circulating VLDL cholesterol level ( J:133453 )

• mice have higher VLDL levels than LDL levels

increased circulating free fatty acids level ( J:133453 )

increased circulating triglyceride level ( J:133453 )

• plasma triglyceride levels are 4-fold higher at 15-16 weeks of age than in wild-type mice

• neither food restriction or leptin treatment has an effect on plasma triglyceride levels

impaired glucose tolerance ( J:133453 )

• glucose intolerance is evident at 7-8 weeks of age and sustained until 15-16 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
abdominal obesity-metabolic syndrome 1		DOID:14221	OMIM:605552	J:133453